Sotrovimab COVID-19 studies. Efficacy is variant dependent. In Vitro studies suggest lower efficacy for omicron BA.1 [Liu, Sheward, VanBlargan] and no efficacy for omicron BA.2 [Zhou]. US EUA has been revoked. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary].
Recent:Shapiro Goodwin Evans Zheng Shimizu Gliga Woo.
Sotrovimab has been officially adopted
in 36 countries.
Submit updates/corrections .
Mar 30 |
(Preprint) (meta analysis) | Sotrovimab for COVID-19: real-time meta analysis of 16 studies |
| Statistically significant improvement is seen for hospitalization. 7 studies from 7 independent teams in 3 different countries show statistically significant improvements in isolation (4 for the most serious outcome). • Meta analysis us.. | ||
Mar 24 |
et al., medRxiv, doi:10.1101/2023.03.21.23287410 (Preprint) | Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial |
| RCT 982 high risk outpatients in the USA reporting that intramuscular sotrovimab was non-inferior to intravenous administration. Death and hospitalization was more frequent with intramuscular administration, without statistical significan.. | ||
Mar 15 |
et al., PLOS ONE, doi:10.1371/journal.pone.0281915 | Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK |
| 75% lower mortality [p=0.55] and 60% lower hospitalization [p=0.35]. Retrospective 604 outpatients in the UK, showing lower risk of hospitalization with sotrovimab treatment, without statistical significance due to the small number of hospitalizations. | ||
Jan 25 |
et al., Journal of Infection, doi:10.1016/j.jinf.2023.02.012 | Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study |
| 27% lower combined mortality/hospitalization [p=0.03]. Retrospective high risk outpatients in the UK, showing lower hospitalization/death with sotrovimab treatment. Residual confounding is likely with adjustments having no detail on specific comorbidities. | ||
Jan 22 |
et al., medRxiv, doi:10.1101/2023.01.20.23284849 (Preprint) | Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform |
| 4% lower combined mortality/hospitalization [p=0.91]. OpenSAFELY retrospective 7,683 outpatients in the UK, showing no significant difference in hospitalization/death between paxlovid and sotrovimab. | ||
Dec 8 |
et al., Microbiology Spectrum, doi:10.1128/spectrum.04103-22 | Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study |
| 140% higher mortality [p=0.12]. PSM retrospective 1,254 hospitalized patients in Germany, 147 treated with sotrovimab, showing higher mortality with sotrovimab, without statistical significance. | ||
Nov 16 |
et al., BMJ, doi:10.1136/bmj-2022-071932 | Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform |
| 50% lower combined mortality/hospitalization [p=0.005]. Retrospective 3,331 sotrovimab and 2,689 molnupiravir patients in the UK, showing lower risk of combined hospitalization/death with sotrovimab. | ||
Oct 6 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac527 | Demographics and outcomes of initial phase of COVID-19 Medicines Delivery Units across 4 UK centres during peak B1.1.529 omicron epidemic: a service evaluation |
| 258% higher hospitalization [p=0.15]. Retrospective 186 patients in the UK treated with sotrovimab, and 222 eligible but declining treatment, showing no significant difference in hospitalization. No group details are provided and the results are subject to confounding by indi.. | ||
Oct 5 |
et al., Research Square, doi:10.21203/rs.3.rs-2118653/v1 (Preprint) | Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate coronavirus disease 2019 during the Omicron variant pandemic |
| 8% higher progression [p=0.73]. Retrospective 1,921 patients in Japan, showing no significant difference in progression with sotrovimab use. | ||
Oct 3 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac802 | Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron-Infected Immunocompromised Patients |
| Prospective analysis of 57 COVID-19 patients receiving sotrovimab, showing rapid creation of escape mutations within immunodeficient patients. Combined treatment with remdesivir reduced the creation of escape variants. | ||
Sep 16 |
et al., Scientific Reports, doi:10.1038/s41598-022-19993-w | Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells |
| In Vitro study showing no antibody-dependent enhancement (ADE) with sotrovimab. ADE was seen for casirivimab/imdevimab within a specific concentration range. | ||
Sep 11 |
et al., medRxiv, doi:10.1101/2022.09.07.22279497 (Preprint) | Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United States |
| 88% lower mortality [p<0.0001] and 61% lower hospitalization [p<0.0001]. Retrospective 1,530,501 high-risk patients in the USA, 15,633 treated with sotrovimab, showing significantly lower mortality and hospitalization with treatment. Sotrovimab maintained efficacy throughout the period analyzed - September 202.. | ||
Sep 9 |
et al., Infection, doi:10.1007/s15010-022-01914-8 | Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study |
| 20% higher severe cases [p=0.79]. Retrospective 218 COVID+ lung transplant patients in Germany, showing no significant difference in severe cases with early sotrovimab use. | ||
Aug 1 |
et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkac256 | Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge |
| 35% lower hospitalization [p=0.46], 66% fewer combined hospitalization/ER visits [p=0.01], and 90% lower progression [p=0.009]. Retrospective high-risk outpatients in the USA, 82 treated with remdesivir, 88 with sotrovimab, and 90 control patients, showing significantly lower combined hospitalization/ER visits with both treatments in unadjusted results. The domina.. | ||
Jul 28 |
et al., Clinical Kidney Journal, doi:10.1093/ckj/sfac177 | Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients |
| Retrospective 82 kidney transplant recipients treated with sotrovimab, showing lower risk of serious COVID-19 outcomes with early treatment. | ||
Jun 18 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.10.002 (date from earlier preprint) | Change in Effectiveness of Sotrovimab for Preventing Hospitalization and Mortality for At-risk COVID-19 Outpatients During an Omicron BA.1 and BA.1.1-Predominant Phase |
| 38% lower mortality [p=0.62], 18% lower hospitalization [p=0.32], and 3% higher progression [p=0.83]. Retrospective 30,247 outpatients in the USA, showing no significant differences with sotrovimab with omicron BA.1. | ||
Apr 21 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.09.023 (date from earlier preprint) | Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar |
| 165% higher progression [p=0.19]. Retrospective 345 sotrovimab treated patients in Qatar matched with 583 patients that opted not to receive treatment, showing higher progression with treatment, without statistical significance. | ||
Apr 5 |
(News) | FDA updates Sotrovimab emergency use authorization |
| FDA has revoked sotrovimab's authorization in all regions due to predicted low efficacy with BA.2, and BA.2 exceeding 50% prevalence in all regions. | ||
Apr 5 |
et al., medRxiv, doi:10.1101/2022.04.03.22273360 (Preprint) | Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients |
| 89% lower mortality [p=0.05] and 62% lower hospitalization [p=0.002]. Retrospective 522 sotrovimab patients and matched controls in the USA, showing significantly lower hospitalization and mortality with treatment. | ||
Mar 5 |
et al., Antibiotics, doi:10.3390/antibiotics11030345 | Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study |
| 56% lower ICU admission [p=0.35] and 59% lower progression [p=0.05]. Retrospective 19 sotrovimab patients and 75 controls is Singapore, showing lower progression with treatment. | ||
Feb 16 |
et al., bioRxiv, doi:10.1101/2022.02.15.480166 (Preprint) (In Vitro) | SARS-CoV-2 Omicron BA.2 Variant Evades Neutralization by Therapeutic Monoclonal Antibodies |
| In Vitro study showing that omicron BA.2 evades all monoclonal antibodies tested, including sotrovimab and tixagevimab/cilgavimab which retained activity for omicron BA.1. | ||
Dec 23 2021 |
et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00751-9 | Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial |
| 2% higher mortality [p=0.96] and 11% improved recovery [p=0.29]. RCT with 182 sotrovimab patients and 178 control patients, median 8 days from symptom onset, showing no significant differences and terminated early due to futility. | ||
Dec 21 2021 |
et al., medRxiv, doi:10.1101/2021.12.18.21267628 (Preprint) | Resistance conferring mutations in SARS-CoV-2 delta following sotrovimab infusion |
| Retrospective 100 sotrovimab patients in Australia, 23 PCR+ more than 10 days post-infusion (68 with status unknown), showing rapid development of spike gene mutations that have been shown to confer high level resistance to sotrovimab in .. | ||
Dec 20 2021 |
et al., bioRxiv, doi:10.1101/2021.12.19.473354 (Preprint) (In Vitro) | Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron) |
| In Vitro study showing that omicron is substantially resistant to neutralization by monoclonal antibodies REGN10933, REGN10987, Ly-CoV016 and Ly-CoV555. S309 (the parent of Sotrovimab) had only 2-fold loss in potency. | ||
Dec 17 2021 |
et al., bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro) | An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies |
| In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal ch.. | ||
Dec 15 2021 |
et al., bioRxiv, doi:10.1101/2021.12.14.472719 (Preprint) (In Vitro) | Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2 |
| In Vitro study (Vero-E6-TMPRSS2) showing 18 of 19 monoclonal antibodies were no longer effective or significantly impaired with B.1.1.529 omicron. | ||
Dec 4 2021 |
et al., JAMA, doi:10.1001/jama.2022.2832 (results published 12/4/21) | Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19 |
| 89% lower ventilation [p=0.12], 75% lower progression [p=0.0004], and 79% lower combined mortality/hospitalization [p=0.0004]. RCT 1,057 outpatients, 529 treated with sotrovimab, showing significantly lower hospitalization >24h or mortality with treatment. | ||
May 26 2021 |
et al., NEJM, doi:10.1056/NEJMoa2107934 (news release 5/26/2021) (Preprint) | Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab |
| 91% lower ICU admission [p=0.06] and 81% lower hospitalization [p=0.0007]. Interim results from the COMET-ICE trial showing significantly lower hospitalization with treatment. NCT04545060. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.